Zobrazeno 71 - 80
of 264
pro vyhledávání: '"Ajjai Alva"'
Autor:
Leslie A. Fecher, Vincent T. Ma, Jessica Waninger, Kent A. Griffith, Ajjai Alva, Stephanie Daignault-Newton, Christopher D. Lao
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Recent studies report of liver metastases (LM) as a poor prognostic factor in patients treated with immune checkpoint inhibitors (ICIs),1 but clinical outcomes associated with different ICI regimens remains uncertain. In this study, we inv
Publikováno v:
Cancer Treatment and Research Communications, Vol 25, Iss, Pp 100251-(2020)
Introduction Immune checkpoint inhibitors (CPIs) were recently approved in advanced clear cell renal cell carcinoma (RCC) and could be a promising option for metastatic RCC with sarcomatoid differentiation (sRCC) which otherwise carry a poor prognosi
Autor:
Vincent T. Ma, Leslie A. Fecher, Zoey Chopra, Alangoya Tezel, Michael D. Green, Jessica Waninger, Bruce G. Redman, Ajjai Alva, Stephanie Daignault-Newton, Christopher D. Lao, Sara Journey
Publikováno v:
Pigment cellmelanoma researchREFERENCES. 34(3)
Nearly half of all metastatic melanoma patients possess the BRAF V600 mutation. Several therapies are approved for advanced stage melanoma, but it is unclear if there is a differential outcome to various immunotherapy regimens based on BRAF mutation
Autor:
Sandy T. Liu, Vadim S. Koshkin, Jayanshu Jain, Monika Joshi, Matthew D. Galsky, Noah M. Hahn, Lucia Alonso Buznego, Marcus Marie Moses, Jure Murgic, Ali Raza Khaki, Tyler F. Stewart, Aristotelis Bamias, Guru Sonpavde, Daniel Castellano, Evan Shreck, Joseph J. Park, Ajjai Alva, Mehmet Asim Bilen, Alexandra Drakaki, Yousef Zakharia, Mark P. Lythgoe, Ariel Ann Nelson, Roubini Zakopoulou, Ang Li, Ivan de Kouchkovsky, Rafael Morales-Barrera, Petros Grivas, Veena Shankaran, Christopher J. Hoimes, Vivek Kumar, Pedro Isaacsson Velho, Ignacio Duran, Abhishek Tripathi, Leonidas Nikolaos Diamantopoulos, Michael Edward Devitt, Pedro C. Barata, Ana Fröbe, Lucia Carril-Ajuria, Evan Y. Yu, Alejo Rodriguez-Vida, Victor Sacristan Santos, Neeraj Agarwal, Alexander Sankin, Benjamin A. Gartrell, Gary H. Lyman, David J. Pinato, Natalie J. Miller
Publikováno v:
Eur Urol Oncol
European urology oncology, vol 4, iss 3
European urology oncology, vol 4, iss 3
Background: While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L) setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for platinum (cisplatin/carboplatin)-unfit patients, response rates r
Autor:
Robert J, Motzer, Eric, Jonasch, Shawna, Boyle, Maria I, Carlo, Brandon, Manley, Neeraj, Agarwal, Ajjai, Alva, Katy, Beckermann, Toni K, Choueiri, Brian A, Costello, Ithaar H, Derweesh, Arpita, Desai, Saby, George, John L, Gore, Naomi, Haas, Steven L, Hancock, Christos, Kyriakopoulos, Elaine T, Lam, Clayton, Lau, Bryan, Lewis, David C, Madoff, Brittany, McCreery, M Dror, Michaelson, Amir, Mortazavi, Lakshminarayanan, Nandagopal, Phillip M, Pierorazio, Elizabeth R, Plimack, Lee, Ponsky, Sundhar, Ramalingam, Brian, Shuch, Zachary L, Smith, Bradley, Somer, Jeffrey, Sosman, Mary A, Dwyer, Angela D, Motter
Publikováno v:
J Natl Compr Canc Netw
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on recent updates to the guidelines, inclu
Autor:
Thomas Powles, Michiel S van der Heijden, Daniel Castellano, Matthew D Galsky, Yohann Loriot, Daniel P Petrylak, Osamu Ogawa, Se Hoon Park, Jae-Lyun Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, Bernhard J Eigl, Howard Gurney, Som D Mukherjee, Yves Fradet, Iwona Skoneczna, Marinos Tsiatas, Andrey Novikov, Cristina Suárez, André P Fay, Ignacio Duran, Andrea Necchi, Sophie Wildsmith, Philip He, Natasha Angra, Ashok K Gupta, Wendy Levin, Joaquim Bellmunt, Michiel S. van der Heijden, Jae Lyun Lee, Bernhard J. Eigl, Som D. Mukherjee, Cristina Suarez, Hans Westgeest, Aude Flechon, Yen-Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez-Valderrama, Susanna Cheng, Stephen Frank, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala Sridhar, Giorgio Vittorio Scagliotti, Jens Voortman, Boris Alekseev, Anna Alyasova, Boris Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, Jose Angel Arranz, Djura Piersma, Sang Joon Shin, Oleg Karyakin, Ignacio Delgado, Jose Luis Gonzalez, See-Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, Monserrat Domenech, Yen-Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, Vasileios Georgoulias, Sasja Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott Tagawa, Pawel Zalewski, Florence Joly, Gencay Hatiboglu, Luca Gianni, Franco Morelli, Rosa Tambaro, Yasuhiro Hashimoto, Alexander Nosov, Albert Font, Alejo M. Rodriguez-Vida, Robert Jones, Naveen Vasudev, Sandhya Srinivas, Jingsong Zhang, Thierry Gil, Daygen Finch, Marc-Oliver Grimm, Yu-Li Su, Simon Chowdhury, Christopher Hocking, Eugen Plas, Scott North, Niels Viggo Jensen, Christine Theodore, Florian Imkamp, Avivit Peer, Takashi Kobayashi, Hideki Sakai, Naoto Sassa, Kazuhiro Yoshimura, Maureen Aarts, Ana Ferreira Castro, Marlen Topuzov, Juan Francisco Rodriguez, Federico Jose Vazquez, Yu-Chieh Tsai, Simon Crabb, Syed Hussain, Johanna Bendell, Marine Gross-Goupil, Gravis Gwenaelle, Raanan Berger, Galina Statsenko, Linda Evans, Alexandra Drakaki, Bradley Somer, Ian Davis, James Lynam, Giuliano Borges, Aldo Dettino, André P. Fay, Graziella Martins, Luis Eduardo Zucca, Mads Agerbaek, Haralambos Kalofonos, Eli Rosenbaum, Hideki Enokida, Hiroaki Kikukawa, Kazuo Nishimura, Satoshi Tamada, Motohide Uemura, Yamil Lopez, Jourik Gietema, Marcin Slojewski, Isabel Fernandes, Alexey Smolin, Danish Mazhar, Arash Rezazadeh Kalebasty, Bradley Carthon, Wolfgang Loidl, Fabio Franke, Gustavo Girotto, Nimira Alimohamed, Robyn Macfarlane, Helle Pappot, Guenter Niegisch, Dimitrios Mavroudis, Avishay Sella, Camillo Porta, Shin Ebara, Motonobu Nakamura, Wataru Obara, Norihiko Okuno, Nobuo Shinohara, Mikio Sugimoto, Akitaka Suzuki, Noriaki Tokuda, Hiroji Uemura, Akito Yamaguchi, Francisco Ramirez, Pawel Rozanowski, Pawel Wiechno, Bhumsuk Keam, Nikolay Kislov, Denis Plaksin, Irfan Cicin, Satish Kumar, Matthew D. Galsky, Daniel P. Petrylak, Joseph Rosales, Ulka Vaishampayan, Stephane Culine, Christos Papandreou, Taketoshi Nara, Mustafa Erman, Laurence Kreiger, Juliana Janoski, Diogo Rosa, Mariana Siqueira, Christina Canil, Lisa Sengelov, Jean-Marc Tourani, Gaku Arai, Katsuyoshi Hashine, Mutsushi Kawakita, Noboru Nakaigawa, Hayahito Nomi, Hiroaki Shiina, Hiroyoshi Suzuki, Junji Yonese, Roberto Kuri, Eleazar Macedo, Samuel Rivera, Alberto Villalobos Prieto, Anna Polakiewicz-Gilowska, Renata Zaucha, Fabio Lopes, Roman Ponomarev, Mark Pomerantz, Shahrokh Shariat, Cynthia Luk, Krzysztof Lesniewski-Kmak
Publikováno v:
lancet oncology, 21(12), 1574-1588. Lancet Publishing Group
Lancet Oncology, 21(12), 1574-1588. Lancet Publishing Group
DANUBE study investigators & Voortman, J 2020, ' Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE) : a randomised, open-label, multicentre, phase 3 trial ', Lancet Oncology, vol. 21, no. 12, pp. 1574-1588 . https://doi.org/10.1016/S1470-2045(20)30541-6
The Lancet Oncology, 21(12), 1574-1588. ELSEVIER SCIENCE INC
Lancet Oncology, 21(12), 1574-1588. Lancet Publishing Group
DANUBE study investigators & Voortman, J 2020, ' Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE) : a randomised, open-label, multicentre, phase 3 trial ', Lancet Oncology, vol. 21, no. 12, pp. 1574-1588 . https://doi.org/10.1016/S1470-2045(20)30541-6
The Lancet Oncology, 21(12), 1574-1588. ELSEVIER SCIENCE INC
Background: Survival outcomes are poor for patients with metastatic urothelial carcinoma who receive standard, first-line, platinum-based chemotherapy. We assessed the overall survival of patients who received durvalumab (a PD-L1 inhibitor), with or
Autor:
Ganesh S. Palapattu, Srinivas Nallandhighal, Todd M. Morgan, Angel Qin, Jae Eun Choi, Simpa S. Salami, A. Kasputis, Alexander Zaslavsky, A. Putelo, J. Stangl-Kremser, Tomasz Maj, Mackenzie Adams, Weiping Zou, Xuhong Cao, Sungsu Lee, S. Patel, Aaron M. Udager, Zachery R. Reichert, Ajjai Alva, Rohit Mehra, Madelyn Lew
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Strategies that interfere with the binding of the receptor programmed cell death protein-1 (PD-1) to programmed death ligand-1 (PD-L1) have shown marked efficacy against many advanced cancers, including those that are negative for PD-L1. Precisely wh
Autor:
Isaac R. Francis, Kimberly L. Shampain, Phillip L. Palmbos, Galina Kirova-Nedyalkova, Kenny H. Cha, Alon Z. Weizer, Ravi K. Samala, Nathaniel B. Meyer, Ajjai Alva, Lubomir M. Hadjiiski, Matthew S. Davenport, Sean Woolen, Elaine M. Caoili, Prasad R. Shankar, Richard H. Cohan, Daniel Barkmeier, Heang Ping Chan
Publikováno v:
Tomography
Tomography; Volume 6; Issue 2; Pages: 194-202
Volume 6
Issue 2
Pages 194-202
Tomography; Volume 6; Issue 2; Pages: 194-202
Volume 6
Issue 2
Pages 194-202
We evaluated the intraobserver variability of physicians aided by a computerized decision-support system for treatment response assessment (CDSS-T) to identify patients who show complete response to neoadjuvant chemotherapy for bladder cancer, and th
Autor:
Jing Li, Arul M. Chinnaiyan, Wojciech Szeliga, Xiong Li, Shuang Wei, Ajjai Alva, Yijian Yan, Jiali Yu, Weiping Zou, Ying Xu, Michael D. Green, Yingjie Bian, Marcin Cieslik, Alicia Ali, Shasha Li, Reema Hamasha, Jiajia Zhou, Weichao Wang, Weimin Wang, Houjun Xia, Sara Grove, Heng Lin, Ilona Kryczek, Gaopeng Li, Jae Eun Choi, Linda Vatan
Publikováno v:
Cancer Cell
Summary Immunotherapy induces durable clinical responses in a fraction of patients with cancer. However, therapeutic resistance poses a major challenge to current immunotherapies. Here, we identify that expression of tumor stanniocalcin 1 (STC1) corr